関連する実験動画
Updated: Sep 9, 2025

05:10
Multidisciplinary Approach to Obesity Management: A Case Report
Published on: May 30, 2025
347
GLP-1受容体アゴニストの自殺行動への影響:ランダム化制御試験に基づくメタ分析
Jingqi Chen1, Qiufeng Zhang1, Qingping Wu1
1The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, China.
Journal of diabetes
|September 1, 2025
まとめ
2型糖尿病 (T2DM) または肥満患者の自殺行動と有意な関連性はない. この25件のRCTのメタ解析では,様々なサブグループとGLP-1型RAにおいてリスクの増加は認められなかった.
科学分野:
- 内分泌学
- 精神科
- 薬用警戒について
背景:
- グルカゴン類ペプチド-1受容体アゴニスト (GLP- 1 RAs) は,2型糖尿病 (T2DM) と肥満の管理に広く使用されています.
- GLP-1 RAの使用と自殺行動の潜在的な関連性について懸念が提起されています.
- このリスクを明確にするには 確固たる証拠が必要です
研究 の 目的:
- GLP-1 RAの曝露と自殺行動の発生率との関連を評価するメタ分析を行う.
- T2DMおよび/または肥満の患者集団でこの関連性を評価する.
主な方法:
- 主要な電子データベース (PubMed,Web of Science,Cochrane Library,ClinicalTrials.gov) で,包括的な文献検索が行われました.
- 25件のランダム化対照試験 (RCT) のデータが含まれていた.
- リスク比 (RR) と95%信頼区間 (95%CI) を計算して関連性を定量化した.
主要な成果:
- 全体的なメタ解析では,GLP-1RAと対照群の自殺行動の発生率において有意な差異は認められなかった (RR = 0. 84,95%CI: 0.5 4 - 1.32,p = 0. 46).
- 状態 (T2DM,肥満),年齢 (青少年,成人),特定のGLP-1RA,および比較薬 (プラセボ) によるサブグループ分析も有意な関連性を示さなかった.
- 思考,自殺未遂,うつ病関連自殺,自殺完了など,特定のタイプの自殺行為において,有意な差異は認められなかった.
結論:
- T2DMまたは肥満の患者では,GLP-1RAの使用は自殺行動のリスクの増加と有意に関連していないことを示唆しています.
- これらの結果は,自殺行動に関するGLP-1RAの安全性プロファイルに関して安心感を与えます.
関連する概念動画
Glucagon-like Receptor Agonists
416
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
416
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
395
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
395
Dipeptidyl Peptidase 4 Inhibitors
252
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
252
G-protein Coupled Receptors
121.2K
G-protein coupled receptors are ligand binding receptors that indirectly affect changes in the cell. The actual receptor is a single polypeptide that transverses the cell membrane seven times creating intracellular and extracellular loops. The extracellular loops create a ligand specific pocket which binds to neurotransmitters or hormones. The intracellular loops holds onto the G-protein.
121.2K
Oral Hypoglycemic Agents: Biguanides and Glitazones
288
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
288
Antidepressant Drugs: MAOIs and Other Agents
340
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
340

